Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials.

Wim Wuyts,Danielle Antin-Ozerkis,J Terrill Huggins,Peter P LaCamera,Paolo Spagnolo,Martina Vašáková,Marlies S Wijsenbeek,Boris Polman,Klaus-Uwe Kirchgaessler,Mary Beth Scholand

Respiratory Medicine（2019）

引用 4|浏览18

暂无评分

摘要

•Safety data from 1082 patients who received placebo in 6 IPF trials were analyzed.•A total of 673 SAEs and 93 deaths were reported; 60 deaths were respiratory-related.•The most frequent SAEs were respiratory-, infection-, and cardiac-related.•These placebo data could act as a comparator to treatment arms in future IPF trials.

查看译文

关键词

Idiopathic pulmonary fibrosis,Interstitial lung disease,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要